-
公开(公告)号：US20210246216A1
公开(公告)日：2021-08-12
申请号：US17242199
申请日：2021-04-27
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20200079857A1
公开(公告)日：2020-03-12
申请号：US16390197
申请日：2019-04-22
摘要： The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
-
公开(公告)号：US20160090419A1
公开(公告)日：2016-03-31
申请号：US14963414
申请日：2015-12-09
IPC分类号： C07K16/28 , A61K47/26 , A61K47/20 , A61K39/395 , A61K47/18
CPC分类号： C07K16/2866 , A61K9/0019 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/20 , A61K47/26 , A61K2039/505 , C07K1/14 , C07K2317/24 , C07K2317/76
摘要： The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
摘要翻译： 要解决的问题是提供稳定且适合于皮下给药的抗体制剂，其中在长期储存期间可防止二聚化和脱酰胺化。 本申请涉及一种稳定的含抗体的液体制剂，其特征在于含有精氨酸和甲硫氨酸。
-
公开(公告)号：US20220281988A1
公开(公告)日：2022-09-08
申请号：US17752978
申请日：2022-05-25
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20240317869A1
公开(公告)日：2024-09-26
申请号：US18656957
申请日：2024-05-07
IPC分类号： C07K16/28 , A61K9/00 , A61K39/00 , A61K39/395 , A61K47/18 , A61K47/20 , A61K47/26 , C07K1/14
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/20 , A61K47/26 , C07K1/14 , A61K9/0019 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20230340134A1
公开(公告)日：2023-10-26
申请号：US18335789
申请日：2023-06-15
CPC分类号： C07K16/2866 , A61K39/39591 , A61K47/183 , A61K47/26 , C07K1/14 , A61K39/3955 , A61K47/20 , A61K9/0019
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20230167183A1
公开(公告)日：2023-06-01
申请号：US18162368
申请日：2023-01-31
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39591 , A61K47/20 , A61K47/26 , A61K47/183 , C07K1/14 , A61K9/0019
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
